Chronicles in drug discovery.

Abstract

New brief reports this month describe five timely topics: IDO inhibitors have demonstrated antitumor properties by increasing immune response to tumors and improving chemotherapy effectiveness. One of the current therapeutic efforts for Alzheimer's disease is directed towards blocking the gamma-secretase activity, thus reducing amyloid-beta production. Patients with premature ovarian failure (POF), at present mainly treated with hormone replacement therapy, are belated for novel treatment options. Selective ERbeta agonists are anticipated to emerge as therapeutics for the treatment of various diseases including inflammatory bowel syndrome, endometriosis, dementia and cognitive disorders. Phospholipase A2 inhibitors specific for enzyme isoforms are actively studied as potential antiallergic/antiasthmatic drugs, antiarthritic agents and therapeutics for atherosclerosis.

• Authors: V Khurdayan, M Cullell-Young
• Journal: Drug news & perspectives (Drug News Perspect) Vol. 18 Issue 4 Pg. 277-80 (May 2005) ISSN: 0214-0934 [Print] United States
• PMID: 16034484 (Publication Type: Journal Article)
• Copyright: 2005 Prous Science. All rights reserved

Chemical References

• Enzyme Inhibitors
• Estrogen Receptor beta
• Indoleamine-Pyrrole 2,3,-Dioxygenase
• Tryptophan Oxygenase
• Phospholipases A
• Phospholipases A2
• Amyloid Precursor Protein Secretases
• Endopeptidases
• Aspartic Acid Endopeptidases
• BACE1 protein, human

Topics

• Amyloid Precursor Protein Secretases
• Aspartic Acid Endopeptidases (antagonists & inhibitors)
• Endopeptidases
• Enzyme Inhibitors (therapeutic use)
• Estrogen Receptor beta (agonists)
• Female
• Humans
• Indoleamine-Pyrrole 2,3,-Dioxygenase
• Phospholipases A (antagonists & inhibitors)
• Phospholipases A2
• Primary Ovarian Insufficiency (drug therapy)
• Tryptophan Oxygenase (antagonists & inhibitors)